Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HSV-2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

NCT06698575
View directory record Official record
Conditions
Recurrent Genital Herpes Simplex Type 2
Interventions
ABI-1179, ABI-1179 Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

NCT05432583
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
BNT163, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT00362297
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir, valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 30, 2026, 3:50 PM EDT
Terminated Phase 4 Interventional Results available

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

NCT00161434
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
valacyclovir, placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

NCT00158860
View directory record Official record
Conditions
Herpes Genitalis
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 30, 2026, 3:50 PM EDT
Withdrawn Not applicable Interventional

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721
View directory record Official record
Conditions
Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions
Placebo, Valacyclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 30, 2026, 3:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population

NCT00655434
View directory record Official record
Conditions
Herpes Simplex Virus 2
Interventions
Not listed
Lead sponsor
Focus Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01346475
View directory record Official record
Conditions
Genital Herpes
Interventions
Valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 2 Interventional

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

NCT02114060
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 2 Interventional

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

NCT02515175
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Matrix-M2, GEN-003, Placebo
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 30, 2026, 3:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2

NCT01112956
View directory record Official record
Conditions
Genital Herpes
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
16 Years to 55 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1 Interventional

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

NCT00231049
View directory record Official record
Conditions
Genital Herpes
Interventions
AG-707
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

NCT01453075
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 2 Interventional

Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study

NCT02300142
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg)
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 30, 2026, 3:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru

NCT00023582
View directory record Official record
Conditions
HIV Infections, Herpes Genitalis, HIV Seronegativity, Syphilis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Oct 30, 2026, 3:50 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Herpes Simplex Type 2 Co-infection in Veterans With Chronic Hepatitis C

NCT01037621
View directory record Official record
Conditions
Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions
Valacyclovir
Drug
Lead sponsor
G.V. (Sonny) Montgomery VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 30, 2026, 3:50 PM EDT
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 30, 2026, 3:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity

NCT02432404
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
NuvaRing
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 30, 2026, 3:50 PM EDT